The latest research & treatment news about Hepatitis C infection, diagnosis, symptoms and treatment.

Sovaldi™ (sofosbuvir) and Hepatitis C

Can those co-infected with HIV and Hepatitis C begin Sovaldi™ combination therapy?

Yes. Efficacy of Sovaldi™ has been assessed in 223 patients with HCV and HIV-1 coinfection. The safety profile of those with coinfection was similar to those observed in HCV mono-infected study subjects. For those subjects receiving atazanavir as part of the antiretroviral regimen, 94% had elevated total bilirubin (grade 3 or 4). None of the subjects had concomitant transaminase increases though. Of the subjects not taking atazanavir, grade 3 or 4 elevated total bilirubin was observed in 1.5% of subjects, which rate is similar to that observed with HCV mono-infected subjects receiving Sovaldi™ and ribavirin in Phase 3 trials.

Last Updated: July 2014

"Full Prescribing Information." Gilead.com. Gilead Sciences, Inc., http://www.gilead.com/~/media/Files/pdfs/medicines/liver-disease/sovaldi/sovaldi_pi.pdf. Retrieved December 31, 2013.

"Patient Information: Sovaldi™." Gilead.com. Gilead Sciences, Inc., http://www.gilead.com/~/media/Files/pdfs/medicines/liver-disease/sovaldi/sovaldi_patient_pi.pdf. Retrieved December 31, 2013.

"Register for a SOVALDI Co-pay Coupon." Sovaldi.com. Gilead Sciences, Inc., https://www.sovaldi.com/copay-register.aspx. Retrieved December 31, 2013.

"Support Path." MySupportPath.com. Gilead Sciences, Inc., http://www.mysupportpath.com/. Retrieved December 31, 2013.

"U.S. Food and Drug Administration Approved Gilead's Sovaldi (Sofosbuvir) for the Treatment of Chronic Hepatitis C." Gilead.com. Gilead Sciences, Inc., http://investors.gilead.com/phoenix.zhtml?c=69964&p=irol-newsArticle&ID=1882800&highlight=. Retrieved December 31, 2013.